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Relationship between the Occurrence of Thromboembolism 
and INR Measurement Interval in Low Intensity Anticoagulation 
after Aortic Mechanical Valve Replacement
Sangho  Rhie,  M.D.*,  Jun  Young  Choi,  M.D.*,  In  Seok  Jang,  M.D.*,  Jong  Woo  Kim,  M.D.*, 
Chung  Eun  Lee,  M.D.*,  Hyun  Oh  Park,  M.D.*
Background:  We investigated changes in the International Normalized Ratio (INR) and its measurement interval in 
patients with thromboembolic events who were treated by low intensity anticoagulation therapy after isolated me-
chanical aortic valve replacement. Materials and Methods: Seventy-seven patients who underwent surgery from 
June 1990 to September 2006 were enrolled in the study and observed until August 2008. The patients were fol-
lowed up at 4∼8 week intervals and their warfarin (Coumadin)
Ⓡ dosage was adjusted aiming for a target range 
of INR 1.5∼2.5. The rate of thromboembolic events was obtained. Changes in the mean INR and INR measure-
ment interval were comparatively analyzed between the normal group (event free group, N=52) who had no anti-
coagulation-related complications and the thromboembolic group (N=10). Hospital records were reviewed retrospec-
tively.  Results: The observation period was 666.75 patient-years. Thromboembolic events occurred in 10 patients. 
The linearized occurrence rate of thromboembolism was 1.50%/patient-years. Actuarial thromboembolism-free rates 
were 97.10±2.02% at 5 years, 84.30±5.22% at 10 years, and 67.44±12.14% at 15 years. The percentages of INR 
within the target range and mean INR were not statistically significantly different for the normal and thromboembolic 
groups. However, the mean INR during the segmented period just before the events showed a significantly lower 
level in the thromboembolic group (during a 4 month period: normal group, 1.86±0.14 vs. thromboembolic group, 
1.50±0.28, p＜0.001). The mean intervals of INR measurement during the whole observation period showed no 
significant differences between groups, but in the segmented period just before the events, the interval was sig-
nificantly longer in thromboembolic group (during a 6 month period: normal group, 49.04±9.47 days vs. thromboem-
bolic group, 65.89±44.88 days, p＜0.01).  Conclusion: To prevent the occurrence of thromboembolic events in pa-
tients who receive isolated aortic valve replacement and low intensity anticoagulation therapy, we suggest that it 
would be safe to maintain an INR level above 1.8 and to measure the INR at least every 7∼8 weeks.
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INTRODUCTION
    Although  experience  of  anticoagulation  treatment  after  me-
chanical  prosthetic  valve  replacement  has  accumulated,  the 
proper  level  of  anticoagulation  remains  controversial. 
Over-dosage  of  Coumadin,  which  is  an  oral  anticoagulant, 
can  result  in  bleeding  and  under-dosage  can  bring  on  the 
complication  of  a  thromboembolic  event,  so  it  is  very  im-
portant  for  patients  and  doctors  to  try  to  maintain  an  ad-
equate INR level (International Normalized Ratio), which is a 
value  used  for  making  dosage  decisions.  Determining  an  ad-
equate  anticoagulation  level  and  maintaining  the  compliance 
of patients are important. A higher INR could reduce the ten-
dency  toward  thromboembolic  events  but  increase  the  ten-
dency toward bleeding, so it is better to maintain the INR as 
low  as  possible,  while  staying  within  the  range  that  lowers 
thromboembolic  events. 
    The  American  College  of  Chest  Physicians  (ACCP)  have 
suggested  a  standard  level  of  INR  to  be  2.5  (2.0  to  3.0)  for 
patients  who  have  bi-leaflet  mechanical  prosthetic  valves  in 
normal sinus rhythm [1]. However, there have been a number 
of  stu dies ab out th e ad equate lev el of  IN R,  an d also  tr ials to  
determine  the  proper  anticoagulation  treatment  (level  of  anti-
coagulation) [2-5]. There are ethnic differences in response to 
anticoagulation  therapy,  so  a  lower  INR  has  been  suggested 
for  Asian  than  for  Westerners  [6-9].  The  authors  have  also 
reported an adequacy of INR ranging from 1.5 to 2.5 [10]. In 
order to prevent thromboembolic events, the good compliance 
of  patients  is  essential  [4].  In  this  study,  the  patients  lived 
near  the  hospital,  so  we  checked  the  patient’s  INR  at  inter-
vals  of  4  to  8  weeks.  We  reviewed  the  relationship  between 
thromboembolic events and the mean INR and INR measure-
ment interval in patients who had undergone mechanical pros-
thetic  aortic  valve  replacements  and  maintained  the  level  of 
INR  from  1.5  to  2.5. 
MATERIALS AND METHODS
    We  reviewed  patient  records  up  to  August  2008  and  ob-
tained  the  rate  of  thromboembolic  events  of  the  77  patients 
who had undergone surgeries from June 1990 until September 
2006.  We  analyzed  the  mean  IN R  a n d  th e  I N R  m e a s u r e m e n t  
interval  between  the  normal  group  (N=52)  which  had  no 
complications related to oral anticoagulation treatment and the 
group  (N=10)  with  thromboembolic  events.   
    We measured the INR whenever patients visited the hospi-
tal with at intervals of 4 to 8 weeks. When the INR was out 
of  the range  of the  target  or varied  widely,  we shortened the 
INR  measurement  interval. 
    We titrated the dosage of oral warfarin sodium (Coumadin
Ⓡ) 
according to the INR, and did not use antiplatelet agents. We 
reviewed  the  medical  records  retrospectively. 
    We  regarded  a  thromboembolic  event  as  an  end  point.  We 
judged  symptoms  and  signs  as  a  thromboembolic  event  if 
they were consistent with the ischemia or infarction of a ma-
jor  organ  even  without  a  definite  diagnosis  of  thromboem-
bolism.  We  analyzed  the  thromboembolism  incidence  and  its 
long-term  results.  Furthermore,  we  compared  and  analyzed 
the mean INR and the INR measurement interval between the 
normal  group  (N=52)  without  complications  related  to  anti-
coagulation  therapy  and  the  thromboembolism  event  group 
(N=10). 
    We  calculated  the  mean  INR  during  the  four  months  just 
before  the  thromboembolic  events  in  order  to  determine  the 
changes  in  the  INR  right  before  thromboembolic  complica-
tions.  The  reason  we  calculated  the  mean  INR  over  the 
course  of  four  months  was  to  obtain  the  results  of  INR  at 
least  twice  during  that  period.  We  calculated  the  mean  INR 
measurement  interval  during  the  six  months  right  before  the 
thromboembolic  events  so  as  to  determine  the  relationship  of 
the complication and the INR measurement interval.  We cal-
culated  the  INR  measurement  interval  during  the  six  months 
in  order  to  obtain  the  INR  measurement  interval  at  least 
twice. 
    We  present  the  cumulative  variables  as  mean  and  standard 
deviation,  and  the  linearized  occurrence  rate  as  %/pa-
tient-year.  We  used  Kaplan-Meier  analysis  for  the  long-term 
results  of  thromboembolism  and  distinguished  the  differences 
between the groups with the Student’s t-test. We regarded the 
value  of  p＜0.05  as  significant.
RESULTS
    The  median  age  at  surgery  was  53  years  old  (16  to  72). Sangho Rhie, et al
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Fig. 1. Actuarial freedom rate from thromboembolism.
Table 1. Comparison of percentages within target range  (INR 
1.5∼2.5) 
EF  (N=52) TE  (N=10) p-value
Percentages  within 
  target  range  (%)
Mean  INR  during  the 
  observed  period
Mean  INR  during  the 
 s e g m e n t e d  4 - m o n t h  
 p e r i o d  b e f o r e  t h e  e v e n t  
59.12±11.80
1.857±0.135
1.857±0.135
58.11±13.21
1.798±0.111
1.504±0.279
 p = 0 . 4 0
 p = 0 . 3 6 7
 p ＜0.001
N=Number  of  patients;  INR=International  normalized  ratio; 
EF=Event  free  (normal)  group;  TE=Thromboembolic  group.
Table 2. Comparison of the interval of INR measurement be-
tween groups
EF  (N=52) TE  (N=10) p-value
Mean  interval  during 
  the  observed  period 
 ( d a y )
Interval  during  the
 s e g m e n t e d  6 - m o n t h
 p e r i o d  b e f o r e  t h e
  event  (day)
49.04±9.48
49.04±9.47
45.12±14.30
65.89±44.88
 p = 0 . 1 4
 p ＜0.01
N=Number  of  patients;  INR=International  normalized  ratio; 
EF=Event  free  (normal)  group;  TE=Thromboembolic  group.
We  applied  various  valves  to  the  patients  according  to  re-
gional  characteristics.  The  valves  were  of  6  types:  St.  Jude, 
Carbomedics, ATS, SORIN, ON-X, and ATS-AP. We did not 
perform  an  analysis  according  to  valve  type  because  of  the 
small  sample  size.   
  During the follow-up period of 666.75 pt-yr, there were 10 
cases  of  thromboembolism,  which  means  a  1.50%/pt-yr  line-
arized  occurrence  rate.  According  to  Kaplan-Meier  analysis, 
the  actuarial  freedom  rates  from  thromboembolism  were 
97.10±2.02%  at  5  years,  84.30±5.22%  at  10  years,  and 
67.44±12.14%  at  15  years  (Fig.  1).
    We  compared  the  rate  of  target  maintenance  between  the 
thromboembolism  event  group  (N=10)  and  the  normal  group 
(N=52)  without  complications  related  to  anticoagulation.  The 
INR  of  all  patients  varied  within  the  range  of  0.9  to  11.97. 
We  targeted  an  INR  range  from  1.5  to  2.5.  There  was  no 
significant  difference  in  the  mean  maintenance  rate  between 
the  normal  group  (N=52)  and  the  thromboembolic  event 
group  (N=10),  which  was  59.12±11.80%,  58.11±13.21%  in 
each  group,  respectively  (p=0.40)  (Table  1). 
  T h e  m e a n  I N R  w a s  1 . 8 6 ±0.14  in  the  normal  group  and 
1.80±0.11  in  the  event  group,  and  the  difference  between 
these  two  was  not  significant  (p=0.367)  (Table  1).  However, 
we  analyzed  the  INR  during  the  4  months  right  before  each 
event, and the mean INR of the normal group was 1.86±0.14 
and  that  of  the  event  group  was  1.50±0.28.  That  means  the 
event  group  had  a  significantly  lower  INR  value  (p≤0.001) 
(Table 1). The normal group did not have any complications, 
so  we  analyzed  the  value  of  the  normal  group  for  the  whole 
period. 
  The INR measurement interval over the whole study period 
was  49.04±9.48  days  in  the  normal  group  and  45.1±14.3 
days  in  the  event  group.  Therefore,  there  was  no  significant 
difference  between  the  two  groups  (p=0.14)  (Table  2).  How-
ever, when we observed the INR measurement interval during 
the  6  months  right  before  events,  the  mean  interval  of  the 
event  group  was  65.89±44.88  days.  That  was  significantly 
longer  than  the  mean  interval  of  the  normal  group,  which 
was  49.04±9.48  days  (p＜0.01)  (Table  2).
DISCUSSION
    INR,  which  is  a  standardized  measurement  of  anti-
coagulation,  has  been  used  widely  since  the  recommendation 
by  the  WHO  [11].  In  addition,  in  order  to  prevent  the  pa-
tients  who  have  mechanical  valves  from  experiencing  throm-
boembolism,  the  need  for  adequate  warfarin  anticoagulation Relationship of the Occurence of Thromboembolism and INR Measurement Interval
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has  been  addressed  [12].  For  this,  it  is  essential  to  maintain 
the  proper  INR.  The  present  study’s  results  on  the  linearized 
occurrence  rate  of  thromboembolism  and  actuarial  event-free 
rates  in  the  patients  who  maintained  a  low  INR  is  similar  to 
those  of  other  reports  [13-17].
    There  have  been  ongoing  trials  which  use  a  low  INR  in 
the  range  of  the  lowest  thromboembolism  rate  whenever 
possible.  Furthermore,  there  have  been  reports  that  showed 
lower  thromboembolic  and  bleeding  rates  with  an  INR  be-
tween  2.0  and  3.0  [2,3].  Although  the  ACCP  suggests  2.5 
(2.0∼3.0)  as  a  target  INR  when  the  left  atrium  is  not  en-
larged [1], the dosage of warfarin needed varies among ethnic 
groups. To maintain the same INR target, Asians require low-
er dosages of warfarin than other ethnic groups [6-9]. You et 
al.  [8]  reported  ethnic  differences  in  bleeding  and  throm-
boembolic rates in a study of Chinese patients in Hong Kong 
who  had  maintained  an  INR  level  from  1.8  to  2.4  and 
showed  low  rate  of  bleeding  and  thromboembolic  compli-
cations.  The  optimum  low  intensity  anticoagulation  therapy 
has  been  reported  in  Korea.  Jeong  et  al.  [5]  reported  that 
there  was  no  statistically  significant  differences  in  throm-
boembolism  occurrence  in  the  groups  with  an  INR  of  1.5  to 
2.0,  2.0  to  2.5,  and  2.5  to  3.0,  and  the  bleeding  rate  was 
higher  in  the  group  with  high  intensity  anticoagulation 
t h e r a p y .  K i m  a n d  K i m  [ 4 ]  s u g g e s t e d  t h a t  a  l o w e r  I N R  f r o m  
1.5  to  2.5  would  be  optimal  for  patients  who  have  mechan-
ical prosthetic aortic valves. The authors have reported an op-
timal  level  from  1.5  to  2.5  in  a  previous  study  [10].  In  the 
present study, the target INR was set at 1.5 to 2.5 for the pa-
tients  who  had  undergone  isolated  mechanical  aortic  valve 
replacement. We used various types of valves, but we did not 
believe that the analysis of individual valves would be mean-
ingful  [18].  There  were  no  differences  in  the  rate  of  target 
INR maintenance or in the mean INR between the groups re-
gardless  of  valve  type.  We  assessed  the  INR  during  the  four 
months  before  complications  occurred,  and  this  value  was 
significantly  different  between  the  two  groups.  The  INR  of 
the  event  group  was  1.50  and  was  significantly  lower  than 
that of the normal group, which was 1.86. This means that a 
certain  period  of  very  low  INR,  rather  than  the  usual  main-
tenance of the mean INR level, can bring on thromboembolic 
events. 
    We  analyzed  the  differences  in  INR  measurement  interval 
between  the  normal  and  the  thromboembolic  event  groups. 
We  reviewed  the  6  months  just  before  the  complications  be-
cause  there  were  no  differences  in  the  INR  measurement  in-
terval of the two groups over the whole observational period. 
The  INR  measurement  interval  of  the  normal  group  was  49 
days  and  that  of  the  event  group  was  66  days.  The  event 
group  showed  lower  patient  compliance  with  taking 
anticoagulants. 
    To  maintain  INR  in  the  target  range  for  the  patients  who 
take  warfarin,  regular  examinatio n s  a r e  e s s e n t i a l .  L i d s t o n e  e t  
al.  [19]  claimed  that  in  some  selected  patients,  they  could 
elongate  the  INR  measurement  interval  to  14  weeks  or  more 
safely;  however, we  believe  this  elongated  interval  is  not op-
timal  because  the  INR  measurement  interval  just  before  the 
complications was 66 days and longer than that of the normal 
group.  In  addition,  the  INR  level  was  lower,  despite  the  fact 
that exams were performed every 4 to 8 weeks in this study. 
We  conclude  that  a  long  INR  measurement  interval  is  poor 
for  maintaining  the  target  INR  and  a  main  cause  of 
complications.  We  often  observe  a  fluctuation  in  the  INR 
even in the patients who have frequent INR measurements, so 
a  long  INR  measurement  interval  is  not  optimal.  However, 
when it comes to the INR measurement interval, further anal-
ysis  and  studies  about  the  factors  which  can  lower  the  INR 
are needed. Just as Kim et al. [4] emphasized the importance 
of  patient compliance,  it  is  suggested  that  clinicians regularly 
educate  patients  about  the  importance  of  taking  warfarin 
daily. 
    Torella  et  al.  [18]  suggested  that  in  the  bi-leaflet  mechan-
ical  aortic  valve  group,  it  would  be  safe  to  maintain  a  low 
i n t e n s i t y  I N R  l e v e l  f r o m  1 . 5  t o  2 . 5 .  T h e i r  m e a n  I N R  w a s  
1.94.  According  to  the  INR  results  from  this  study,  because 
of the higher risk of thromboembolism, the target INR should 
be  over  1.8  despite  an  application  of  low  intensity  anti-
coagulation  therapy.   
CONCLUSION
    We  suggest  that  to  maintain a n  I N R  l e v e l  o v e r  1 . 8  a n d  
INR measurement interval of 7 to 8 weeks would be safe for 
preventing  thromboembolic  even t s  w h e n  a  l o w  l e v e l  o f  a n t i -Sangho Rhie, et al
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coagulation  treatment  is  applied  after  isolated  mechanical 
aortic  valve  replacement. 
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